Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year

ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13555-021-00657-y) contains supplementary material, which is available to authorized users.

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, de Bruin-Weller, Marjolein, Simpson, Eric L., Chen, Zhen, Ardeleanu, Marius, Rossi, Ana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776905/
https://www.ncbi.nlm.nih.gov/pubmed/34994968
http://dx.doi.org/10.1007/s13555-021-00657-y
_version_ 1784636940418547712
author Blauvelt, Andrew
de Bruin-Weller, Marjolein
Simpson, Eric L.
Chen, Zhen
Ardeleanu, Marius
Rossi, Ana B.
author_facet Blauvelt, Andrew
de Bruin-Weller, Marjolein
Simpson, Eric L.
Chen, Zhen
Ardeleanu, Marius
Rossi, Ana B.
author_sort Blauvelt, Andrew
collection PubMed
description ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13555-021-00657-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8776905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-87769052022-02-02 Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year Blauvelt, Andrew de Bruin-Weller, Marjolein Simpson, Eric L. Chen, Zhen Ardeleanu, Marius Rossi, Ana B. Dermatol Ther (Heidelb) Commentary ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13555-021-00657-y) contains supplementary material, which is available to authorized users. Springer Healthcare 2022-01-07 /pmc/articles/PMC8776905/ /pubmed/34994968 http://dx.doi.org/10.1007/s13555-021-00657-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Blauvelt, Andrew
de Bruin-Weller, Marjolein
Simpson, Eric L.
Chen, Zhen
Ardeleanu, Marius
Rossi, Ana B.
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
title Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
title_full Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
title_fullStr Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
title_full_unstemmed Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
title_short Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
title_sort consistency of response to dupilumab in adults with moderate-to-severe atopic dermatitis over 1 year
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776905/
https://www.ncbi.nlm.nih.gov/pubmed/34994968
http://dx.doi.org/10.1007/s13555-021-00657-y
work_keys_str_mv AT blauveltandrew consistencyofresponsetodupilumabinadultswithmoderatetosevereatopicdermatitisover1year
AT debruinwellermarjolein consistencyofresponsetodupilumabinadultswithmoderatetosevereatopicdermatitisover1year
AT simpsonericl consistencyofresponsetodupilumabinadultswithmoderatetosevereatopicdermatitisover1year
AT chenzhen consistencyofresponsetodupilumabinadultswithmoderatetosevereatopicdermatitisover1year
AT ardeleanumarius consistencyofresponsetodupilumabinadultswithmoderatetosevereatopicdermatitisover1year
AT rossianab consistencyofresponsetodupilumabinadultswithmoderatetosevereatopicdermatitisover1year

Ejemplares similares